Zoetis Q2 2026: Net income falls 4.8% to $691M as U.S. companion animal revenue drops 11%

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 5, 2025 · ~2 min read

Key Changes

• high

  Securities class action filed May 2026 alleges false statements about safety and market share of four major companion animal products (Librela, Simparica Trio, Apoquel, Cytopoint) from Jan 2025 through May 2026; multiple derivative suits followed in June.

  Notes: Securities class action litigation view on EDGAR →
• high

  U.S. companion animal revenue fell 11% in Q2 2026 (vs. 9% growth in Q2 2025), driven by softer demand, competitive pressure on dermatology and Simparica Trio, generic competition on Cerenia/Convenia, and lower Librela sales.

  MD&A: U.S. companion animal revenue decline verify on EDGAR →
• high

  Issued $2.0B in 0.250% convertible notes due 2029 (Dec 2025); net proceeds funded $187M in capped calls, $248M concurrent buyback, and $1.5B additional repurchases completed by March 2026. Buyback spend totaled $1.2B in H1 2026 vs. $781M in H1 2025.

  MD&A: Convertible notes and buyback verify on EDGAR →